PriceTargets.com logo

Acutus Medical - AFIB Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.03 As of 09/6/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for AFIB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acutus Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AFIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AFIB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Acutus Medical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.03.

This chart shows the closing price for AFIB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Acutus Medical. This rating has held steady since August 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2022The Goldman Sachs GroupReiterated RatingNeutral$1.50Low
8/15/2022BTIG ResearchBoost Target$2.50Low
6/24/2022BTIG ResearchLower TargetBuy$2.00 ➝ $1.50Low
4/27/2022BTIG ResearchUpgradeNeutral ➝ BuyHigh
3/31/2022William BlairReiterated RatingMarket PerformLow
1/20/2022BTIG ResearchDowngradeBuy ➝ NeutralHigh
1/14/2022Canaccord Genuity GroupLower TargetBuy ➝ Hold$10.00 ➝ $3.00High
1/14/2022UBS GroupDowngradeBuy ➝ HoldHigh
11/29/2021BTIG ResearchReiterated RatingBuy$8.00High
11/12/2021BTIG ResearchLower TargetNeutral ➝ Buy$20.00 ➝ $8.00High
11/12/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
10/22/2021The Goldman Sachs GroupInitiated CoverageNeutral$10.00High
3/25/2021JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Neutral$19.00Low
3/25/2021William BlairReiterated RatingOutperform ➝ Market PerformLow
3/19/2021William BlairDowngradeOutperform ➝ Market Perform$39.00 ➝ $19.00High
3/19/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$39.00 ➝ $19.00High
1/14/2021Bank of AmericaDowngradeBuy ➝ Neutral$38.00 ➝ $30.00Low
9/17/2020BTIG ResearchReiterated RatingBuy$40.00High
8/31/2020William BlairInitiated CoverageOutperformHigh
8/31/2020BTIG ResearchInitiated CoverageBuy$40.00High
8/31/2020Bank of AmericaInitiated CoverageBuy$38.00High
8/31/2020JPMorgan Chase & Co.Initiated CoverageOverweight$39.00High
(Data available from 9/7/2019 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/10/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2024
  • 1 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2024
  • 1 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
5/10/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/9/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/8/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/7/2024

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Acutus Medical logo
Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $0.03
Low: $0.03
High: $0.04

50 Day Range

MA: $0.03
Low: $0.03
High: $0.04

52 Week Range

Now: $0.03
Low: $0.03
High: $0.79

Volume

255,791 shs

Average Volume

1,031,626 shs

Market Capitalization

$936.24 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Acutus Medical?

The following Wall Street sell-side analysts have issued stock ratings on Acutus Medical in the last year:
View the latest analyst ratings for AFIB.

What is the current price target for Acutus Medical?

0 Wall Street analysts have set twelve-month price targets for Acutus Medical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Acutus Medical in the next year.
View the latest price targets for AFIB.

What is the current consensus analyst rating for Acutus Medical?

Acutus Medical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AFIB.

What other companies compete with Acutus Medical?

Other companies that are similar to Acutus Medical include Venus Concept, Helius Medical Technologies, Quoin Pharmaceuticals, Sintx Technologies and Nuwellis. Learn More about companies similar to Acutus Medical.

How do I contact Acutus Medical's investor relations team?

Acutus Medical's physical mailing address is 2210 FARADAY AVE SUITE 100, CARLSBAD CA, 92008. The company's listed phone number is 442-232-6080 and its investor relations email address is [email protected]. The official website for Acutus Medical is www.acutusmedical.com. Learn More about contacing Acutus Medical investor relations.